Business
OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival
OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival\n\nOncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival\n\nBATON ROUGE, LA--(Marketwired - September 26, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announces that OncBioMune Chief Executive Officer Dr. Jonathan Head will be making an abstract poster presentation today at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The conference is being hosted at the Sheraton New York Times Square Hotel in New York, New York from September 25-28. Dr. Head is scheduled to make the presentation titled, \"Phase 1 clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients,\" during the Reception and Poster Session A from 5:00-7:30 PM ET today at New York Hilton Midtown, Americas Halls I & II.Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax® is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.Forward-Looking StatementsThis press release contains forw...